By David Wild
Data from AllianceRx Walgreens Prime have provided a glimpse into the impact interleukin-17 (IL-17) inhibitors are having on the management of psoriasis.
Researchers who presented their findings at the 2019 National Association of Specialty Pharmacy (poster 2) annual meeting, in Washington, D.C., discovered that nearly half of patients with psoriasis who switched to an IL-17 inhibitor from a non-IL-17 biologic reported improvements in their symptoms. Also, adherence improved by over